Oxford Biomedica plc: Preliminary results for the year ended 31 December 2018

NEXT STORY
Myriad’s myPath® Melanoma Test Receives Medicare Coverage
PREV STORY
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2018 Financial Results and Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

author_avatar
NASDAQ Market News

Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01

author_avatar
NASDAQ Market News

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

author_avatar
NASDAQ Market News